tradingkey.logo

AstraZeneca's Anselamimab In AL Amyloidosis Did Not Meet Primary Endpoint In Overall Patient Population

ReutersJul 16, 2025 6:08 AM

- AstraZeneca PLC AZN.L:

  • ASTRAZENECA PLC - UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS

  • ASTRAZENECA: RESULTS DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT IN OVERALL PATIENT POPULATION

  • ASTRAZENECA PLC - EVALUATION OF ANSELAMIMAB RESULTS ONGOING

  • ASTRAZENECA: ANSELAMIMAB SHOWED CLINICALLY MEANINGFUL IMPROVEMENT IN TIME TO ACM, FREQUENCY OF CVH IN PRESPECIFIED SUBGROUP OF PATIENTS VERSUS PLACEBO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI